- Home
- A-Z Publications
- Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents)
- Previous Issues
- Volume 10, Issue 2, 2011
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents) - Volume 10, Issue 2, 2011
Volume 10, Issue 2, 2011
-
-
Editorial [Hot-Topic: Molecular Mechanisms in Rheumatic Diseases:Rationale for Novel Drug Development (Guest Editor: Charles J. Malemud)]
More LessNovel therapies for the treatment of rheumatoid arthritis (RA) appear to be on the horizon. Any advances in the development of novel therapeutics for RA will only be made possible as a result of our improved understanding of how immune-mediated inflammation contributes to the pathogenesis and progression of the RA disease process. Thus, recent advances in unraveling the way in which ‘cross-talk’ between intr Read More
-
-
-
Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development - Introduction
More LessNovel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Developme Read More
-
-
-
Dysfunctional Immune-Mediated Inflammation in Rheumatoid Arthritis Dictates that Development of Anti-Rheumatic Disease Drugs Target Multiple Intracellular Signaling Pathways
More LessA skewed repertoire of pro-inflammatory cytokines produced by the Th1 subset, one of the hallmarks of rheumatoid arthritis (RA), is characterized by an overabundance of pro-inflammatory cytokines. Tumor necrosis factor-α, interleukin- 1 (IL-1), IL-6, IL-7, IL-8, IL-21, IL-12/IL-23, IL-15, IL-17, IL-18, IL-32, and interferon-γ are primarily responsible for immune-mediated inflammation of RA by activating Janus kinases (JAK) -1, -2, -3 Read More
-
-
-
Computational Strategies for the Development of Novel Small Molecule Rheumatoid Arthritis Therapies
Authors: Tarek M. Mahfouz and David H. KinderRheumatoid arthritis is a chronic autoimmune disorder that causes joint disfigurement and destruction leading to reduced quality of life. Effective drug therapies include the Disease Modifying Anti-Rheumatic Drugs which can help impede the progression of the disease but are not always effective. It is, therefore important to identify novel and effective therapies to combat this debilitating disorder. Several bioinformatics to Read More
-
-
-
Current and Future Therapeutic Targets of Rheumatoid Arthritis
Authors: Yuan Ming Di, Zhi-Wei Zhou, Chun Guang Li and Shu-Feng ZhouRheumatoid arthritis (RA) is a chronic systematic autoimmune disease which affects about 1% of the population world wide. This article aimed to identify current therapeutic targets for RA based on data from the literature and drug target related databases. Identified targets were further analysed using a powerful bioinformatics tool, PANTHER (Protein ANalysis THrough Evolutionary Relationships). Additionally, we explored Read More
-
-
-
Immunological Targets in Inflammation from the Small Molecule Perspective
Inflammation and autoimmune disorders have received much greater attention in the recent years due to the elucidation of various molecular mechanisms and the discoveries of various cytokines and other proteins involved in these processes. These discoveries are helping develop novel therapeutics including small molecules and protein therapeutics (biologics) for the treatment of sterile and nonsterile inflammatory disor Read More
-
-
-
Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Authors: P. J. Higgins, M. Draper and M. NelsonTetracyclines possess anti-inflammatory characteristics which are largely independent of their antibacterial activity. A variety of in vitro biologic effects have been reported for tetracyclines in both immune and non-immune cells. The in vivo therapeutic efficacy of tetracyclines in diseases such as rheumatoid arthritis, multiple sclerosis, and stroke has also been demonstrated in both animal models and clinical studies. This r Read More
-
Volumes & issues
-
Volume 24 (2025)
-
Volume 23 (2024)
-
Volume 22 (2023)
-
Volume 21 (2022)
-
Volume 20 (2021)
-
Volume 19 (2020)
-
Volume 18 (2019)
-
Volume 17 (2018)
-
Volume 16 (2017)
-
Volume 15 (2016)
-
Volume 14 (2015)
-
Volume 13 (2014)
-
Volume 12 (2013)
-
Volume 11 (2012)
-
Volume 10 (2011)
-
Volume 9 (2010)
-
Volume 8 (2009)
-
Volume 7 (2008)
-
Volume 6 (2007)
-
Volume 5 (2006)
Most Read This Month
Article
content/journals/aiaamc
Journal
10
5
false
en
